Forecast

The analysts' average price target is €17.26 (-52.84%). The median is €17.26 (-52.84%).

Buy	1
Hold	0
Sell	0

News Go to news feed

Mind Medicine presents phase-3 strategy for MM120 after positive phase-2b data

Mind Medicine presented results and plans for MM120 at the TD Cowen Summit: the phase-2b study showed a significant 7.7-point improvement versus placebo after 12 weeks in generalized anxiety disorder, with a remission rate of 48% and a response rate of 65% in the 100-microgram group. The company has received Breakthrough Therapy designation from the FDA and plans a phase-3 program to assess long-term efficacy in GAD and to pursue MDD as an indication. Operationally, Mind Medicine intends to shorten monitoring times, test an ODT formulation, and optimize dosing and placebo management; adverse effects were mainly perceptual symptoms on the day of treatment. » More on de.investing.com
MindMed reports progress in phase 3 trials and solid financial position

MindMed is advancing the development of its phase 3 trials for novel therapies targeting generalized anxiety disorder and major depression, supported by $238 million in cash reserves. The company expects key trial results in 2026 and considers itself financially secure at least through 2027. Despite rising R&D expenses, MindMed remains optimistic about the market potential and regulatory approval of its drug candidates. » More on de.investing.com

Financials

In the last quarter, Mind Medicine (MindMed) had revenue of €0 and net profit of -€139.31M

(EUR)	Jun 2026	YoY
Revenue	0	-
Gross profit	0	-
Net profit	-139.31M	284.13%
EBITDA	-65.78M	91.89%

Fundamentals

Metric	Value
Market capitalization	€1.35B
Number of shares	75.55M
52-week high/low	€18.19 - €4.06
Dividends	No
Beta	2.62
P/E ratio	-12.74
PEG ratio	0.17
P/B ratio	5.28
P/S ratio	0.00

Company profile

Mind Medicine (MindMed) Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt neuartige Produkte zur Behandlung von Hirnleistungsstörungen in den Bereichen Psychiatrie, Sucht, Schmerz und Neurologie. Das Unternehmen entwickelt MM-120, das sich in Phase 2 zur Behandlung der generalisierten Angststörung und der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung sowie zur Behandlung chronischer Schmerzen befindet, und MM-110, einen cholinergen a3ß4-Nicotinrezeptor-Antagonisten, der die Phase 1 zur Behandlung des Opioid-Entzugs abgeschlossen hat. Darüber hinaus entwickelt das Unternehmen MM-402, ein R-Enantiomer von 3,4-Methylendioxymethamphetamin für die Behandlung von Kernsymptomen der Autismus-Spektrum-Störung. Der Hauptsitz des Unternehmens befindet sich in Vancouver, Kanada.

Name	Mind Medicine (MindMed)
CEO	Robert Barrow
Headquarters	Vancouver, bc Canada
Website	mindmed.co
Sector	Health Care
Industry	Pharmaceuticals
IPO	11/15/2016
Employees	74